Credit Suisse analyst Tiago Fauth raised the firm’s price target on BioMarin to $127 from $110 and keeps an Outperform rating on the shares. The firm notes BioMarin reported financial results for the quarter, in-line with consensus revenues of $538M but missing on non-GAAP earnings of $67M. These results were driven by the continued strength of Voxzogo, offset by higher-than-expected operating expenses and slightly lower Palynziq uptake.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BMRN:
- BioMarin sees FY23 EPS under new method of $1.80-$2.05, consensus $1.61
- BioMarin reports Q4 EPS (0c), consensus (7c)
- BioMarin Announces Record Fourth Quarter and Full Year 2022 Total Revenues Driven by Strong Global Demand for VOXZOGO® and Steady Growth of Enzyme Business
- Notable companies reporting after market close
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations